Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-Dose 9vHPV Vaccine in Chinese Girls vs 3-Dose in Women
NCT05450705Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Primary completion
- Aug 2029
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Merck & Co.. Started Jul 2022; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT05450705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05450705.